PortfoliosLab logoPortfoliosLab logo
NTLA vs. PLTR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NTLA vs. PLTR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intellia Therapeutics, Inc. (NTLA) and Palantir Technologies Inc. (PLTR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NTLA achieves a 34.71% return, which is significantly higher than PLTR's -27.99% return.


NTLA

1D
-1.94%
1M
-7.49%
YTD
34.71%
6M
34.26%
1Y
45.73%
3Y*
-35.92%
5Y*
-32.32%
10Y*
-7.62%

PLTR

1D
-2.36%
1M
-4.48%
YTD
-27.99%
6M
-30.28%
1Y
-6.85%
3Y*
99.99%
5Y*
39.00%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

NTLA vs. PLTR - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
NTLA
Intellia Therapeutics, Inc.
34.71%-22.90%-61.76%-12.61%-70.49%117.35%151.74%
PLTR
Palantir Technologies Inc.
-27.99%135.03%340.48%167.45%-64.74%-22.68%135.50%

Correlation

The correlation between NTLA and PLTR is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.28

Correlation (3Y)
Calculated over the trailing 3-year period

0.30

Correlation (5Y)
Calculated over the trailing 5-year period

0.42

Correlation (All Time)
Calculated using the full available price history since Sep 30, 2020

0.41

The correlation between NTLA and PLTR shifts across timeframes, from 0.28 (1 year) to 0.42 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NTLA:

$1.43B

PLTR:

$329.05B

EPS

NTLA:

-$3.58

PLTR:

$0.89

PS Ratio

NTLA:

20.19

PLTR:

62.90

PB Ratio

NTLA:

2.31

PLTR:

38.94

Total Revenue (TTM)

NTLA:

$66.09M

PLTR:

$5.22B

Gross Profit (TTM)

NTLA:

-$33.92M

PLTR:

$4.39B

EBITDA (TTM)

NTLA:

-$299.32M

PLTR:

$2.01B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NTLA vs. PLTR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTLA
NTLA Risk / Return Rank: 6060
Overall Rank
NTLA Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
NTLA Sortino Ratio Rank: 6363
Sortino Ratio Rank
NTLA Omega Ratio Rank: 6565
Omega Ratio Rank
NTLA Calmar Ratio Rank: 5757
Calmar Ratio Rank
NTLA Martin Ratio Rank: 5454
Martin Ratio Rank

PLTR
PLTR Risk / Return Rank: 3838
Overall Rank
PLTR Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
PLTR Sortino Ratio Rank: 3737
Sortino Ratio Rank
PLTR Omega Ratio Rank: 3636
Omega Ratio Rank
PLTR Calmar Ratio Rank: 3939
Calmar Ratio Rank
PLTR Martin Ratio Rank: 3939
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NTLA vs. PLTR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Palantir Technologies Inc. (PLTR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NTLAPLTRDifference
Sharpe ratioReturn per unit of total volatility

+0.57

Sortino ratioReturn per unit of downside risk

+1.07

Omega ratioGain probability vs. loss probability

1.18

1.03

+0.16

Calmar ratioReturn relative to maximum drawdown

0.63

-0.14

+0.77

Martin ratioReturn relative to average drawdown

0.99

-0.25

+1.24

NTLA vs. PLTR - Sharpe Ratio Comparison

The current NTLA Sharpe Ratio is 0.47, which is higher than the PLTR Sharpe Ratio of -0.11. The chart below compares the historical Sharpe Ratios of NTLA and PLTR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NTLA vs. PLTR - Drawdown Comparison

The maximum NTLA drawdown since its inception was -96.45%, which is greater than PLTR's maximum drawdown of -84.62%. Use the drawdown chart below to compare losses from any high point for NTLA and PLTR.


Loading charts...

Drawdown Indicators


NTLAPLTRDifference

Max Drawdown

Largest peak-to-trough decline

-96.45%

-84.62%

-11.83%

Max Drawdown (1Y)

Largest decline over 1 year

-71.27%

-38.22%

-33.05%

Max Drawdown (3Y)

Largest decline over 3 years

-86.28%

-40.61%

-45.67%

Max Drawdown (5Y)

Largest decline over 5 years

-96.45%

-79.14%

-17.31%

Max Drawdown (10Y)

Largest decline over 10 years

-96.45%

Current Drawdown

Current decline from peak

-93.15%

-38.22%

-54.93%

Average Drawdown

Average peak-to-trough decline

-57.11%

-40.27%

-16.84%

Ulcer Index

Depth and duration of drawdowns from previous peaks

45.80%

21.23%

+24.57%

Volatility

NTLA vs. PLTR - Volatility Comparison

Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 24.01% compared to Palantir Technologies Inc. (PLTR) at 17.16%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than PLTR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NTLAPLTRDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.01%

17.16%

+6.85%

Volatility (6M)

Calculated over the trailing 6-month period

54.68%

38.32%

+16.36%

Volatility (1Y)

Calculated over the trailing 1-year period

96.60%

50.83%

+45.77%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

80.85%

65.44%

+15.41%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

78.41%

69.75%

+8.66%

Dividends

NTLA vs. PLTR - Dividend Comparison

Neither NTLA nor PLTR has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

NTLA vs. PLTR - Financials Comparison

This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Palantir Technologies Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B20222023202420252026
15.05M
1.63B
(NTLA) Total Revenue
(PLTR) Total Revenue
Values in USD except per share items

Frequently Asked Questions


NTLA and PLTR have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NTLA has higher volatility (24.01%) compared to PLTR (17.16%). In terms of maximum drawdown, NTLA dropped -96.45% vs PLTR's -84.62%.

NTLA currently has the higher Sharpe Ratio (0.47 vs -0.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NTLA and PLTR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer